SC
CRVS icon

Samlyn Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Samlyn Capital’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,065,935
Closed -$12.9M – 84
2025
Q1 		$12.9M Sell
4,065,935
-2,601,170
-39% -$12.3M 0.19% 73
2024
Q4 		$35.7M Buy
6,667,105
+2,136,772
+47% +$16M 0.54% 59
2024
Q3 		$23.9M Sell
4,530,333
-1,592,688
-26% -$5.72M 0.36% 71
2024
Q2 		$11.1M Buy
6,123,021
+3,774,658
+161% +$7.03M 0.19% 85
2024
Q1 		$4.18M Sell
2,348,363
-147,896
-6% -$309K 0.07% 91
2023
Q4 		$4.39M Buy
2,496,259
+90,495
+4% +$132K 0.09% 74
2023
Q3 		$3.51M Buy
2,405,764
+299,834
+14% +$634K 0.06% 93
2023
Q2 		$4.82M Buy
+2,105,930
New +$4.38M 0.08% 80

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return